Illumina, Inc. (NASDAQ:ILMN) Short Interest Update

Illumina, Inc. (NASDAQ:ILMN) was the target of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 7,210,000 shares, an increase of 10.2% from the November 15th total of 6,540,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 3.8 days.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Leerink Partners raised their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Piper Sandler cut their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Finally, Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $165.95.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently made changes to their positions in the company. Industrial Alliance Investment Management Inc. acquired a new position in Illumina in the second quarter valued at approximately $34,000. TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the period. Massmutual Trust Co. FSB ADV grew its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Illumina in the second quarter worth $61,000. Finally, Private Trust Co. NA lifted its stake in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 1.7 %

Shares of NASDAQ:ILMN traded down $2.56 during mid-day trading on Friday, hitting $143.87. 1,808,556 shares of the company traded hands, compared to its average volume of 2,009,685. The firm has a market cap of $22.82 billion, a P/E ratio of -14.44 and a beta of 1.11. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66. The firm’s 50 day simple moving average is $144.27 and its 200 day simple moving average is $128.44. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 EPS. On average, equities analysts anticipate that Illumina will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.